In Re: National Prescription Opiate Litigation

Track this case

Case overview

Case Number:

1:17-md-02804

See also:

Court:

Ohio Northern

Nature of Suit:

P.I.: Other

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Dan Aaron Polster (MDL 28

Firms

Companies

Government Agencies

Sectors & Industries:

  1. March 23, 2022

    Opioid MDL Bellwether In SF Gets 'Shocking' Cut To Trial Time

    An impending bellwether trial involving San Francisco and several drug companies in multidistrict opioid litigation will be among the shortest opioid trials yet despite shaping up as one of the largest, a California federal judge said Wednesday, an admittedly startling move accompanied by other streamlining efforts.

  2. March 22, 2022

    Pharmacy Attys Risking Opioid MDL Sanctions, Judge Warns

    Lawyers for CVS Pharmacy, Walgreens and Walmart will face discipline if they don't swiftly rectify noncompliance with a "clear and simple" directive to outline remedies after a jury blamed the companies for inundating communities with prescription narcotics, the top judge in multidistrict opioid litigation warned.

  3. March 11, 2022

    Key Opioid Cases To Watch As Massive Wave Of Trials Looms

    Despite sweeping settlements and landmark verdicts, the nation's epic saga of opioid crisis litigation against Big Pharma is far from winding down, with the coming weeks heralding an unprecedented torrent of trials. Here, Law360 shares a detailed map of the opioid trials terrain and explores major lawsuits that are rapidly approaching moments of truth.

  4. March 11, 2022

    6th Circ. Orders Opioid MDL Judge To Unfreeze Cases

    The Sixth Circuit on Friday ordered the Ohio federal judge overseeing opioid multidistrict litigation to rule on remand motions from three Texas counties and two New Mexico cities, finding that the cases have been pending for an "unduly long time."

  5. March 11, 2022

    Schools End Opioid Claims Against J&J, Distributors

    Roughly 40 school districts, largely in Maine, have agreed to end opioid-related claims against Johnson & Johnson following negotiations with the state attorney general to receive a cut of a $26 billion global deal struck in nationwide litigation, an attorney for the schools told Law360 Friday.

  6. March 07, 2022

    CVS, Walgreens, Walmart Can't Escape Opioid Verdict

    The Ohio federal judge overseeing multidistrict litigation over the opioid crisis on Monday refused to strike a jury verdict that held major pharmacy chains liable for fueling the crisis in two Ohio counties, finding there was sufficient evidence at trial for the jury to make its decision and rejecting a request for a new trial.

  7. February 11, 2022

    5 Key Details As Endo Is Rocked Again By Opioid Default

    Tennessee counties and Endo Pharmaceuticals traded bitter claims of legal shenanigans before the drugmaker suffered another default judgment for opioid discovery misconduct, and the bombshell ruling underscores the company's ongoing peril in nationwide opioid litigation, according to court records and experts.

  8. February 01, 2022

    Tribes Reach $590M Opioids Deal With J&J, Distributors

    Native American tribes have agreed to a deal worth nearly $590 million with Johnson & Johnson and major opioid distributors to settle claims over the companies' alleged role in exacerbating the opioid crisis, according to court filings Tuesday.

  9. January 31, 2022

    Pharmacies Can't Get 6th Circ. Review In Ohio Opioid Trial

    The Ohio federal judge overseeing the opioid multidistrict litigation on Monday denied an attempt by CVS, Walgreens and Walmart to get immediate Sixth Circuit review of a juror's misconduct during a recent trial that found the companies liable for their roles in the opioid epidemic, saying a new trial would only prolong the litigation.

  10. January 21, 2022

    $26B Deal Keeps Opioid Files Of J&J, Distributors Out Of View

    Document disclosure obligations that attorneys have touted as crucial elements of opioid litigation settlements are absent from a $26 billion resolution that Johnson & Johnson and large drug distributors are close to finalizing, hindering the deal's goal of preventing narcotic abuse, experts say.